<p>Andrew A. Nierenberg, MD Brief Biosketch</p><p>Dr. Nierenberg is Professor of Psychiatry, Harvard Medical School, Director of the Bipolar Research Program, and Associate Director of the Depression Clinical and Research Program, Massachusetts General Hospital (MGH). He attended the Albert Einstein College of Medicine of Yeshiva University followed by a residency in psychiatry at New York University/Bellevue Hospital and then became a Robert Wood Johnson Clinical Scholar at Yale University. Dr. Nierenberg then ran one of the Affective Disorders Inpatient Units and the Affective Disorders Outpatient Unit at McLean Hospital in Belmont, MA. In 1992, he joined the Psychiatry Department at MGH.</p><p>He has published over 350 original articles and over 60 reviews, editorials, and chapters, and has been listed among the Best Doctors in North America for the treatment of mood and anxiety disorders continuously since 1994. He received the NDMDA Gerald L. Klerman Young Investigator Award and was elected as a member of the American College of Neuropsychopharmacology (ACNP).</p><p>Dr. Nierenberg is the Director of the NIMH Bipolar Trials Network which is currently conducting CHOICE, 10-site nationwide comparative effectiveness trial of lithium and quetiapine. Additionally, the Bipolar Trials Network is in the final stages of completing LiTMUS, an effectiveness trial of low dose lithium alone or in combination with optimized treatment. His primary interests are treatment resistant depression, bipolar depression, and the longitudinal course of mood disorders. Dr. Nierenberg lectures nationally and internationally, teaches and supervises clinicians and researchers, maintains an active clinical practice, conducts clinical trials, and is on the editorial boards of multiple psychiatric journals.</p>